Payload Information
General Information of This Payload
| Payload ID | PAY0HPBPD |
|||||
|---|---|---|---|---|---|---|
| Name | WO2024020536A1+HER-E-37+payload |
|||||
| Synonyms |
WO2024020536A1+HER-E-37+payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C24H21FN2O5 |
|||||
| Isosmiles | CC[C@@](C(C=C1C2=NC3=CC(F)=C(C)C4=C3C(C(O)CC4)=C2CN51)=C(C5=O)CO6)(O)C6=O |
|||||
| InChI |
InChI=1S/C24H21FN2O5/c1-3-24(31)14-6-17-21-12(8-27(17)22(29)13(14)9-32-23(24)30)20-18(28)5-4-11-10(2)15(25)7-16(26-21)19(11)20/h6-7,18,28,31H,3-5,8-9H2,1-2H3/t18?,24-/m0/s1
|
|||||
| InChIKey |
FRPSGSHVDGIPFA-LUTIACGYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
436.439 |
Polar area |
101.65 |
||
Complexity |
1406.93979 |
xlogp Value |
2.50672 |
|||
Heavy Count |
32 |
Rot Bonds |
1 |
|||
Hbond acc |
7 |
Hbond Donor |
2 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
HER-E-49 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
. pM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
HER-E-40 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
36.15 pM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
HER-E-39 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
44.88 pM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
HER-E-37 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
47.82 pM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||